Expert Opinion on Pharmacotherapy

Papers
(The H4-Index of Expert Opinion on Pharmacotherapy is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy37
Comprehensive overview of the available pharmacotherapy for the treatment of non-neurogenic overactive bladder in children36
Rheumatoid arthritis in Latin America: pharmacotherapy and clinical challenges33
Pharmacotherapy developments in autophagy inhibitors for bladder cancer32
Real-world safety and effectiveness of roxadustat in patients with anemia of chronic kidney disease: interim results from a post-marketing surveillance study in Japan30
Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis29
Advances in the management of obstructive hypertrophic cardiomyopathy: The role of mavacamten29
Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy29
Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B28
A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease28
Chemotherapy in resectable or potentially resectable colon cancer with liver metastases26
An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook26
Antidepressant medications in women aged 40 and older and the risk of fragility fractures: a systematic literature review and meta-analysis24
GnRH agonists and antagonists in therapy of symptomatic uterine fibroids – current roles and future perspectives24
Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond23
Current treatment options for Mycobacterium marinum cutaneous infections22
Bexagliflozin for type 2 diabetes: an overview of the data21
How useful is chemotherapy for atypical and anaplastic meningiomas?20
The pharmacological treatment and management of hyperhidrosis20
Zanubrutinib for the treatment of chronic lymphocytic leukemia19
Resmetirom: the first approved therapy for treating metabolic dysfunction associated steatohepatitis19
Momelotinib in myelofibrosis19
Pharmacotherapeutic options in pediatric obesity: an urgent call for further research19
An up-to-date overview of the pharmacotherapeutic options for premature ejaculation19
0.15247011184692